NCT06943521 2025-12-11A Study of MT-4561 in Patients With Various Advanced Solid TumorsTanabe Pharma America, Inc.Phase 1/2 Recruiting27 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04579757 2025-05-08Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsHutchmedPhase 1/2 Terminated87 enrolled 29 charts